Kissei Pharmaceutical Full Year 2025 Earnings: Beats Expectations

Kissei Pharmaceutical (TSE:4547) Full Year 2025 Results

Key Financial Results

• Revenue: JP¥88.3b (up 17% from FY 2024).
• Net income: JP¥12.0b (up 7.2% from FY 2024).
• Profit margin: 14% (down from 15% in FY 2024).
• EPS: JP¥274 (up from JP¥247 in FY 2024).

We've discovered 3 warning signs about Kissei Pharmaceutical. View them for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Kissei Pharmaceutical Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 7.6%.

Looking ahead, revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Japan.

Performance of the Japanese Pharmaceuticals industry.

The company's shares are up 9.5% from a week ago.

Risk Analysis

Before you take the next step you should know about the 3 warning signs for Kissei Pharmaceutical (1 doesn't sit too well with us!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.